Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Gary Yen

Pain Medicine Marlboro, NJ Medical Doctor

NPI 1356383566 CMS profile 106319

17 N Main St, Marlboro, NJ 07746

Open in the dashboard

General payments

$2,415

14 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Gary Yen of Marlboro, NJ is reported in the CMS Open Payments database as having received $2,415 across 14 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 56th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $305 5
2022 General $124 3
2020 General $14 1
2019 General $1,973 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gary Yen
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Gary Yen were reported at $0. Among 1,144 Pain Medicine profiles paid that year, the median was $402 and the middle half received between $130 and $1,173.

Show as a table
Year Gary Yen Pain Medicine median Middle half National median
2019 $1,973 $409 $115–$1,311 $163
2020 $14 $214 $66–$666 $114
2021 $0 $299 $84–$899 $132
2022 $124 $335 $103–$1,149 $149
2023 $305 $376 $114–$1,228 $160
2024 $0 $387 $115–$1,173 $164
2025 $0 $402 $130–$1,173 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. AngioDynamics, Inc. $1,899 2 payments
  2. SPR Therapeutics, Inc $153 2 payments
  3. Horizon Therapeutics plc $124 3 payments
  4. NuVasive, Inc. $92 1 payment
  5. DePuy Synthes Sales Inc. $53 2 payments
  6. Merz North America, Inc. $44 1 payment
  7. Orthogenrx Inc. $21 1 payment
  8. AbbVie, Inc. $16 1 payment
  9. Allergan Inc. $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Travel and Lodging $1,502 1 payment
  2. Food and Beverage $914 13 payments
Products named General payments · program years 2019–2023
  1. SPRINT PNS System $153 2 payments
  2. PENNSAID $124 3 payments
  3. ACP $92 1 payment
  4. ORTHOVISC $53 2 payments
  5. Xeomin $44 1 payment
  6. GenVisc 850 $21 1 payment
  7. BOTOX Facial Aesthetics $16 1 payment
  8. BOTOX Hyperhydrosis $14 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

206

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$3,855

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

27.2%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 28 $1,604
Oxycodone Hcl Generic 27 $659
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 28 $548
Gabapentin Generic 35 $429
Pregabalin Generic 18 $273
Tramadol Hcl Generic 41 $150
Cyclobenzaprine Hcl Generic 13 $106
Alprazolam Generic 16 $88

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 59 billing codes

Paid by Medicare

$370,672

Of which drugs: $7,014

Medicare patients

404

Average age 73

Services billed

7,139

231 women, 173 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 37%
Ischemic heart disease 34%
Chronic kidney disease 20%
Cancer 20%
Depression 20%
Osteoporosis 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose J7324 Office 20 64 $6,200
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 28 197 $150
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 35 240 $22
Injection, ketorolac tromethamine, per 15 mg J1885 Office 13 32 $15

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

14 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record